US Patent No: 7,459,270
Number of patents in Portfolio can not be more than 2000
Modified Vaccinia Ankara virus variant
Stats
-
Dec 2, 2008
Issued date -
Dec 4, 2007
filing date -
11/999,127
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 7,056,723 Method for the recovery and purification of poxviruses from infected cells | 10 | 2002 | |
| 7,097,842 Modified vaccinia virus ankara for the vaccination of neonates | 20 | 2003 | |
| 2006/0029,619 Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | 7 | 2003 | |
| 6,761,893 Modified vaccinia ankara virus variant | 33 | 2003 | |
| 6,913,752 Modified Vaccinia Ankara virus variant | 24 | 2003 | |
| 2006/0127,984 Modified Vaccinia virus Ankara for the vaccination of neonates | 18 | 2006 | |
|
|
|||
| 5,155,020 Recombinant poxvirus host range selection system | 55 | 1989 | |
| 5,338,683 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins | 53 | 1990 | |
| 6,605,465 Methods for avoiding maternal immunity | 10 | 2002 | |
|
|
|||
| 5,753,489 Method for producing viruses and vaccines in serum-free culture | 52 | 1995 | |
| 5,756,341 Method for controlling the infectivity of viruses | 17 | 1995 | |
| 5,770,212 Recombinant poxviruses with foreign DNA in essential regions | 27 | 1997 | |
|
|
|||
| 5,494,807 NYVAC vaccinia virus recombinants comprising heterologous inserts | 89 | 1993 | |
| 5,843,456 Alvac poxvirus-rabies compositions and combination compositions and uses | 17 | 1995 | |
|
|
|||
| 6,663,871 Methods and reagents for vaccination which generate a CD8 T cell immune response | 14 | 1999 | |
| 2004/0131,594 Methods and reagents for vaccination which generate a CD8 T cell immune response | 15 | 2003 | |
|
|
|||
| 6,685,950 Methods of treating viral infections | 11 | 2001 | |
|
|
|||
| 5,405,772 Medium for long-term proliferation and development of cells | 78 | 1993 | |
|
|
|||
| 6,190,655 Methods of using Flt-3 ligand for exogenous gene transfer | 12 | 1998 | |
|
|
|||
| 2003/0138,454 Vaccination method | 14 | 2002 | |
|
|
|||
| 5,789,245 Alphavirus structural protein expression cassettes | 107 | 1996 | |
|
|
|||
| 6,440,422 Recombinant MVA virus, and the use thereof | 18 | 1998 | |
|
|
|||
| 5,185,146 Recombinant MVA vaccinia virus | 62 | 1989 | |
|
|
|||
| 6,976,752 Ink jet printer with resistance compensation circuit | 9 | 2003 | |
|
|
|||
| 6,497,883 Porcine circovirus recombinant poxvirus vaccine | 48 | 2000 | |
|
|
|||
| 6,204,250 Immunization of infants | 19 | 1996 | |
|
|
|||
| 5,403,582 Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus | 19 | 1993 | |
|
|
|||
| 5,597,570 Protein recognized by antibodies raised against native P28 of schistosoma mansoni | 4 | 1992 | |
|
|
|||
| 6,869,793 Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines | 5 | 1999 | |
|
|
|||
| 5,676,950 Enterically administered recombinant poxvirus vaccines | 11 | 1995 | |
|
|
|||
| 2006/0159,699 Flavivirus ns1 subunit vaccine | 7 | 2002 | |
|
|
|||
| 4,191,745 Preparation for the treatment of Herpes zoster and other Herpes infections, as well as method for manufacture thereof | 16 | 1978 | |
| 6,805,870 Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament | 17 | 1996 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jun 2, 2016 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jun 2, 2020 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |